Is Travere Therapeutics profitable?
Travere Therapeutics has achieved significant operational milestones by reporting its first non-GAAP profitable quarters, driven by accelerating commercial sales of its flagship therapeutic product and disciplined operating expense management. While historical development-stage biotechnology companies often burn cash through extensive research phases, its recent financial reports reflect an encouraging transition toward sustained profitability and positive net income generation.
Related FAQs
BlackRock is an institutional investor in Atlassian Corporation, not its owner. As of early 2026, BlackRock reported beneficial ownership of approximately 5.
Executive compensation for Kimberly A. (Kim) Fields, serving as the President and Chief Executive Officer of ATI Inc.
Wall Street equity analysts generally track Travere Therapeutics, traded under the ticker TVTX, with favorable buy recommendations rather than sell ratings, driven by strong commercial adoption of its lead rare kidney disease treatment, FILSPARI.
Evaluating whether Travere Therapeutics represents an attractive purchase involves analyzing its transition toward commercial profitability, rare disease drug pipeline execution, and potential market expansion.
Wall Street equity analysts tracking Trevi Therapeutics, traded under the ticker TRVI, generally issue favorable buy recommendations, driven by promising clinical development updates for its flagship pipeline treatment targeted at chronic cough an...
Travere Therapeutics, traded under the ticker TVTX, is often evaluated by biotech sector analysts as a high-potential yet speculative investment choice.
Analysts monitoring Travere Therapeutics, Inc. (TVTX) maintain a consensus average twelve-month price target hovering around $53.25 to $56.34 per share.
The stock ticker TVTX represents the publicly traded corporate shares of Travere Therapeutics, Inc.